---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Phase of product development"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Phase of product development. Topics: Summary: regulatory status and development history; Regulatory status: Approved; NDA submitted December 2025 and approved November 2026; Launch: Approved November 2026, with commercial availability expected in early December 2026; FDA approval in November 2026; 27 further topics. 31 evidence topics quoted from 26 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Summary: regulatory status and development history

- Approval: the FDA approved Lembaz (adrabetadex) injection under NDA 220996 on November 17, 2026, as a “Type 1 - New Molecular Entity” with priority review and orphan status. The FDA describes it as the first treatment shown to help people with a “severe form of Niemann-Pick disease type C (NPC) live longer”. Beren Therapeutics states that LEMBAZ will be available at commercial treatment sites nationwide in early December.
- Application and review: Beren Therapeutics, through its subsidiary Mandos LLC, submitted the NDA on December 17, 2025 for the treatment of patients with infantile-onset NPC. The application was based on an externally controlled survival analysis, biomarker and nonclinical confirmatory evidence, and patient experience narratives. The FDA granted priority review and assigned a PDUFA target action date of August 17, 2026. Beren's March 18, 2026 response to an FDA information request was classified as a major amendment, which extended the goal date by three months to November 17, 2026. The application was not referred to an FDA advisory committee.
- Designations: the FDA designated 2-hydroxypropyl-B-cyclodextrin an orphan drug for the treatment of Niemann Pick disease, type C on 02/18/2013, with Mandos LLC as the sponsor. The European Commission granted orphan designation EU/3/13/1124 on 26 April 2013 to the International Niemann-Pick Disease Alliance; sponsorship was transferred to Vtesse Europe Limited in February 2015, Mallinckrodt Pharmaceuticals Ireland Limited in September 2018, Rapport Global Strategic Services Ireland Limited in December 2021, and Eliquent Life Sciences Limited in August 2024. Adrabetadex also holds rare pediatric disease designation. The FDA granted Vtesse Breakthrough Therapy designation for VTS-270 in Niemann-Pick Type C1 disease on January 6, 2016 and later rescinded it based on data from a 12-month phase 2b/3 trial; a second Breakthrough Therapy designation, for infantile-onset NPC, was announced on December 9, 2025 and was informed by an externally controlled survival analysis.
- Priority review voucher and patents: the FDA granted a rare pediatric disease priority review voucher (PRV NDA 220996) with the approval, which may be transferred, including by sale. Earlier agreements refer to shares of voucher proceeds: Sucampo agreed in 2017 to pay Vtesse shareholders a share of net proceeds from monetization of the voucher, and the Mallinckrodt plan of reorganization refers to the Debtors' 63% retained ownership interest in the voucher. Beren states that its intellectual property estate provides patent protection through 2046, excluding potential patent term extensions, patent term adjustments, and supplementary protection certificates, and that it holds more than 30 issued U.S. patents.
- Development history: researchers at the NIH National Center for Advancing Translational Sciences and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, in collaboration with Vtesse, developed VTS-270. After its launch in January 2015, Vtesse fully enrolled the registrational study at 20 clinical trial sites. Sucampo acquired Vtesse on April 3, 2017 for upfront consideration of $200 million plus contingent royalties, and Mallinckrodt acquired Sucampo, and with it VTS-270, in February 2018. At a Type A meeting in August 2018, the FDA indicated that approvability would be based on the totality of data; in November 2018 Mallinckrodt announced that the registration trial did not show a statistically significant separation from placebo. In the three months ended December 27, 2019, Mallinckrodt recognized a full impairment of $274.5 million on the VTS-270 asset, “primarily driven by continued regulatory challenges”, and trial NCT03643562 ended after the sponsor determined that the benefit-risk profile of adrabetadex was not favorable. Mandos acquired the program from Mallinckrodt in 2021, held an introductory call and a Type C meeting with the FDA, and completed new analyses of adrabetadex before the NDA submission.
- Earlier timelines: in April 2017 Sucampo expected pivotal trial results in mid-2018 and a launch beginning in 2019, and a YODA Project data request projected an NDA submission by December 2023 toward accelerated approval.

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf); [Drugs@FDA NDA 220996](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220996); [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer); [Beren Therapeutics LEMBAZ approval community update (2026)](https://www.berentx.com/news/community-update-lembaz-adrabetadex-is-approved/); [Beren Therapeutics NDA submission community letter (2025)](https://www.berentx.com/news/adrabetadex-new-drug-application-fda-filing-december-2025/); [Beren Therapeutics NDA submission press release (2025)](https://www.berentx.com/news/adrabetadex-nda-submitted-npc/); [Beren Therapeutics NDA acceptance press release (2026)](https://www.berentx.com/news/adrabetadex-nda-accepted-priority-review-npc/); [Beren Therapeutics review extension press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-fda-extension/); [FDA Orphan Drug Designations and Approvals (2013)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=386412); [EMA orphan designation EU/3/13/1124 (2013)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1124); [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/); [Vtesse Breakthrough Therapy designation press release (2016)](https://www.biospace.com/b-vtesse-inc-b-announces-fda-s-granting-of-breakthrough-therapy-designation-for-vts-270-in-niemann-pick-type-c1-disease); [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm); [Mallinckrodt plan of reorganization exhibit (2021)](https://www.sec.gov/Archives/edgar/data/1567892/000119312521264916/d41435dex993.htm); [Beren Therapeutics patent estate press release (2026)](https://www.berentx.com/news/beren-therapeutics-expands-cyclodextrin-intellectual-property-estate-with-eight-new-u-s-issued-patents/); [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm); [Mallinckrodt Form 10-K (2020)](https://www.sec.gov/Archives/edgar/data/1567892/000156789220000005/mnk10-k122719.htm); [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562); [Mandos May 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-may-2022/); [Beren Therapeutics October 2024 community update (2024)](https://www.berentx.com/news/npc-community-update-october-2024/); [Beren Therapeutics October 2025 community update (2025)](https://www.berentx.com/news/npc-community-update-october-2025/); [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-2.1.1-2"></a>

### Regulatory status: Approved; NDA submitted December 2025 and approved November 2026

> “Please refer to your new drug application (NDA) received December 17, 2025, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Lembaz (adrabetadex) injection.”
> “We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

| Action date | Submission | Action type | Submission classification | Review priority; orphan status |
| --- | --- | --- | --- | --- |
| “11/17/2026” | “ORIG-1” | “Approval” | “Type 1 - New Molecular Entity” | “PRIORITY; Orphan” |

Source: [Drugs@FDA NDA 220996](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220996)

> “We are pleased to share that on December 17, 2025, Beren Therapeutics P.B.C.®, through its subsidiary Mandos LLC®, submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for adrabetadex.”
> “This application seeks approval for the treatment of patients with infantile-onset Niemann-Pick disease type C (NPC).”

Source: [Beren Therapeutics NDA submission community letter (2025)](https://www.berentx.com/news/adrabetadex-new-drug-application-fda-filing-december-2025/)

<a id="topic-2.1.1-3"></a>

### Launch: Approved November 2026, with commercial availability expected in early December 2026

> “LEMBAZ will be available at commercial sites nationwide in early December.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

> “I am so pleased to finally share with you all that today, the U.S. Food and Drug Administration (FDA) approved LEMBAZ™ (adrabetadex).”
> “LEMBAZ will be available at commercial treatment sites nationwide in early December.”

Source: [Beren Therapeutics LEMBAZ approval community update (2026)](https://www.berentx.com/news/community-update-lembaz-adrabetadex-is-approved/)

<a id="topic-2.1.1-4"></a>

### FDA approval in November 2026

> “The U.S. Food and Drug Administration today approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

> “Initial U.S. Approval: 2026”
> “Revised: 11/2026”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.1-5"></a>

### Review timeline: major amendment and three-month extension of the goal date

> “We acknowledge receipt of your major amendment dated March 18, 2026, which extended the goal date by three months.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

> “The new Prescription Drug User Fee Act (PDUFA) target action date is November 17, 2026.”
> “The extension follows Beren’s March 18, 2026 response to an FDA information request that included updates and clarifications to existing data and supporting documentation.”
> “The FDA classified the response as a Major Amendment to the NDA, which under FDA regulations extends the review period by three months.”

Source: [Beren Therapeutics review extension press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-fda-extension/)

<a id="topic-2.1.1-6"></a>

### Basis of the application: externally controlled survival analysis with confirmatory evidence

> “The application was based on data supporting a finding of improved survival in an externally controlled survival analysis, biomarker and nonclinical confirmatory evidence, and patient experience narratives.”

Source: [Beren Therapeutics NDA submission press release (2025)](https://www.berentx.com/news/adrabetadex-nda-submitted-npc/)

> “(VTS-270) in 2021, Mandos has worked closely with the FDA to define the regulatory path supporting this submission, including the design and implementation of an externally-controlled survival analysis.”

Source: [Beren Therapeutics NDA submission community letter (2025)](https://www.berentx.com/news/adrabetadex-new-drug-application-fda-filing-december-2025/)

<a id="topic-2.1.1-7"></a>

### Expedited programs: priority review

> “Priority Review was requested on the basis that the application meets the qualifying criteria”

Source: [Beren Therapeutics NDA submission press release (2025)](https://www.berentx.com/news/adrabetadex-nda-submitted-npc/)

> “The NDA for adrabetadex was granted Priority Review by the FDA, and adrabetadex previously received Orphan Drug Designation and Breakthrough Therapy Designation.”

Source: [Beren Therapeutics review extension press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-fda-extension/)

<a id="topic-2.1.1-8"></a>

### Advisory committee

> “Your application for Lembaz was not referred to an FDA advisory committee because outside expertise was not necessary; there were no controversial issues that would benefit from advisory committee discussion.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="topic-2.1.1-9"></a>

### Breakthrough Therapy designation for infantile-onset disease, December 2025

> “THOUSAND OAKS, Calif.– December 9, 2025 – Beren Therapeutics P.B.C.®, a Public Benefit Corporation and parent company of Mandos LLC®, today announced that Mandos received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for adrabetadex, an investigational drug for infantile-onset Niemann-Pick disease type C (NPC).”
> “The FDA decision was informed by an externally controlled survival analysis that showed adrabetadex improves survival in individuals with infantile-onset NPC and was reviewed alongside supportive biomarker and nonclinical data.”

Source: [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/)

> “Lembaz received Breakthrough Therapy designation.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-2.1.1-10"></a>

### Breakthrough Therapy designation of January 2016, later rescinded

> “GAITHERSBURG, Md., Jan. 6, 2016 /PRNewswire/ -- Vtesse, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status.”
> “Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.”

Source: [Vtesse Breakthrough Therapy designation press release (2016)](https://www.biospace.com/b-vtesse-inc-b-announces-fda-s-granting-of-breakthrough-therapy-designation-for-vts-270-in-niemann-pick-type-c1-disease)

> “Adrabetadex previously received BTD in 2016 under a prior sponsor, and the FDA rescinded the designation based on data from a 12-month Phase 2b/3 clinical trial.”

Source: [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/)

<a id="topic-2.1.1-11"></a>

### Orphan drug designation in the United States, February 2013

| Field | Quoted record |
| --- | --- |
| Generic name | “2-hydroxypropyl-B-cyclodextrin” |
| Date designated | “02/18/2013” |
| Orphan designation | “Treatment of Niemann Pick disease, type C.” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Mandos LLC” |

Source: [FDA Orphan Drug Designations and Approvals (2013)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=386412)

<a id="topic-2.1.1-12"></a>

### Orphan designation in the European Union, April 2013, and transfers of sponsorship

> “On 26 April 2013, orphan designation (EU/3/13/1124) was granted by the European Commission to International Niemann-Pick Disease Alliance (INPDA), the United Kingdom, for 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick disease, type C.”

Source: [EMA orphan designation EU/3/13/1124 (2013)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1124)

| Date | Update |
| --- | --- |
| “August 2024” | “The sponsorship was transferred to Eliquent Life Sciences Limited.” |
| “December 2021” | “The sponsorship was transferred to Rapport Global Strategic Services Ireland Limited.” |
| “September 2018” | “The sponsorship was transferred to Mallinckrodt Pharmaceuticals Ireland Limited.” |
| “February 2015” | “The sponsorship was transferred to Vtesse Europe Limited, United Kingdom.” |

Source: [EMA orphan designation EU/3/13/1124 (2013)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1124)

<a id="topic-2.1.1-13"></a>

### Rare pediatric disease designation

> “Adrabetadex also has Orphan Drug and Rare Pediatric Disease designations.”

Source: [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/)

<a id="topic-2.1.1-14"></a>

### Rare pediatric disease priority review voucher granted at approval

> “We also inform you that you have been granted a rare pediatric disease priority review voucher, as provided under section 529 of the FD&C Act.”
> “This priority review voucher (PRV) has been assigned a tracking number, PRV NDA 220996.”
> “This PRV may be transferred, including by sale, by you to another sponsor of a human drug or biologic application.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

> “The company received a Priority Review Voucher upon this approval.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.1.1-15"></a>

### Priority review voucher proceeds: interests retained by earlier owners

> “Sucampo has acquired Vtesse for an upfront consideration of $200 million, and has agreed to pay Vtesse shareholders contingent consideration based on mid-single digit to double-digit royalties on global net sales of the product based on increasing net sales levels, and a share of net proceeds that may be generated from the monetization of the  pediatric review voucher, which is expected to be granted in connection with the approval of the product in the U.S.”

Source: [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)

> “All proceeds received upon disposition of the Debtors’ 63% retained ownership interest in the priority review voucher related to VTS-270.”

Source: [Mallinckrodt plan of reorganization exhibit (2021)](https://www.sec.gov/Archives/edgar/data/1567892/000119312521264916/d41435dex993.htm)

<a id="topic-2.1.1-16"></a>

### Patent estate statements, August 2026

> “Global intellectual property estate includes issued patents and pending applications supporting adrabetadex and Beren’s broader cholesterol-trafficking pipeline with patent protection through 2046, excluding potential patent term extensions, patent term adjustments, and supplementary protection certificates.”
> “Beren Therapeutics P.B.C., a leader in cholesterol-trafficking biology and novel cyclodextrin-based therapeutics, today announced that the U.S. Patent and Trademark Office has issued eight new U.S. patents related to Beren’s proprietary derivatized cyclodextrins, including adrabetadex, increasing Beren’s U.S. patent portfolio to more than 30 issued patents.”

Source: [Beren Therapeutics patent estate press release (2026)](https://www.berentx.com/news/beren-therapeutics-expands-cyclodextrin-intellectual-property-estate-with-eight-new-u-s-issued-patents/)

<a id="topic-2.1.1-17"></a>

### Development history: origin at the National Institutes of Health and Vtesse

> “Researchers at the NIH's National Center for Advancing Translational Sciences (NCATS) and Eunice Kennedy ShriverNational Institute of Child Health and Human Development (NICHD), in close collaboration with Vtesse, patients and patient advocacy groups, developed VTS-270 as part of a project focused on finding treatments for NPC.”

Source: [Vtesse Breakthrough Therapy designation press release (2016)](https://www.biospace.com/b-vtesse-inc-b-announces-fda-s-granting-of-breakthrough-therapy-designation-for-vts-270-in-niemann-pick-type-c1-disease)

> “Since its launch in January 2015, the Vtesse team has fully enrolled the registrational study of VTS-270 in NPC-1 at 20 clinical trial sites across the globe, providing broad access for study-eligible patients.”

Source: [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)

<a id="topic-2.1.1-18"></a>

### Development history: acquisition of Vtesse by Sucampo, April 2017

> “ROCKVILLE, Md., and GAITHERSBURG, Md., April 03, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, and Vtesse Inc. (Vtesse), a privately-held rare disease company, today announced that Sucampo has acquired Vtesse for upfront consideration of $200 million.”

Source: [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)

<a id="topic-2.1.1-19"></a>

### Development history: acquisition of Sucampo by Mallinckrodt, February 2018

> “In February 2018, the Company acquired Sucampo through the acquisition of all the outstanding common stock of Sucampo.”
> “Through this acquisition, the Company acquired VTS-270, a Phase 3 development product for Niemann-Pick Type C, a complicated, ultra-rare neurodegenerative disease that typically presents in childhood and is ultimately fatal.”

Source: [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm)

<a id="topic-2.1.1-20"></a>

### Development history: phase 2b/3 result and FDA Type A meeting, 2018

> “In November 2018, we announced that the results of our recently completed registration trial for the product did not show a statistically significant separation from placebo.”
> “The FDA indicated at a Type A meeting in August 2018 that their view on the potential approvability will be based on the totality of data, not a single study or endpoint.”
> “We expect that a better understanding of the potential benefit of VTS-270 will emerge as we carefully consider the totality of data available and continue to work with the primary investigators and the FDA to determine the best path forward.”

Source: [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm)

<a id="topic-2.1.1-21"></a>

### Development history: full impairment of the VTS-270 asset, December 2019

> “During the three months ended December 27, 2019, we recognized a full impairment on our IPR&D asset related to VTS-270 of $274.5 million, primarily driven by continued regulatory challenges.”
> “The Company will continue to engage with the FDA and assess future opportunities for the development program.”

Source: [Mallinckrodt Form 10-K (2020)](https://www.sec.gov/Archives/edgar/data/1567892/000156789220000005/mnk10-k122719.htm)

<a id="topic-2.1.1-22"></a>

### Development history: termination of the open-label trial under the prior sponsor

> “Sponsor had determined that the benefit-risk profile of adrabetadex was not favorable and the clinical development program for adrabetadex was discontinued.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-2.1.1-23"></a>

### Development history: transfer of the product from Mallinckrodt to Mandos, 2021

> “Beren, through its subsidiary Mandos, acquired the adrabetadex program from Mallinckrodt in 2021 and has worked closely with the FDA and NPC community to advance adrabetadex’s development and generate the data and analyses that supported the new BTD designation.”

Source: [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/)

> “We are pleased now to report that the final stage of transition from Mallinckrodt to Mandos is complete.”

Source: [Mandos December 2021 community update (2021)](https://www.berentx.com/news/npc-community-update-december-2021/)

<a id="topic-2.1.1-24"></a>

### Development history: FDA meetings under Mandos, 2022 to 2024

> “We have completed our first meeting with the U.S. Food & Drug Administration (FDA).”
> “We recently had an FDA invited introductory call to discuss plans regarding the development of VTS-270 and introduce the Mandos team.”

Source: [Mandos May 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-may-2022/)

> “We are excited to announce the FDA has accepted our request for a Type C Meeting scheduled in October to discuss the direction of our adrabetadex program’s development.”

Source: [Beren Therapeutics September 2024 community update (2024)](https://www.berentx.com/news/npc-community-update-september-2024/)

> “We are pleased to announce we had a productive Type C meeting with FDA on October 10.”

Source: [Beren Therapeutics October 2024 community update (2024)](https://www.berentx.com/news/npc-community-update-october-2024/)

<a id="topic-2.1.1-25"></a>

### PDUFA target action date of August 17, 2026, February 2026, superseded in May 2026

> “Accepted for priority review with Prescription Drug User Fee Act (PDUFA) action date of August 17, 2026”
> “The FDA assigned adrabetadex a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026.”

Source: [Beren Therapeutics NDA acceptance press release (2026)](https://www.berentx.com/news/adrabetadex-nda-accepted-priority-review-npc/)

<a id="topic-2.1.1-26"></a>

### FDA decision timing, December 2025, superseded in February 2026

> “If accepted, we anticipate a regulatory decision regarding the NDA as early as Q3 2026.”

Source: [Beren Therapeutics NDA submission community letter (2025)](https://www.berentx.com/news/adrabetadex-new-drug-application-fda-filing-december-2025/)

<a id="topic-2.1.1-27"></a>

### NDA submission timing, December 2025, superseded in December 2025

> “Beren plans to submit an NDA in the near future and expects adrabetadex to be eligible for Priority Review.”

Source: [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/)

<a id="topic-2.1.1-28"></a>

### NDA submission timing, October 2025, superseded in December 2025

> “Mandos Health has completed the new analyses of adrabetadex and is working towards a New Drug Application (NDA) submission.”

Source: [Beren Therapeutics October 2025 community update (2025)](https://www.berentx.com/news/npc-community-update-october-2025/)

<a id="topic-2.1.1-29"></a>

### NDA submission timing and accelerated approval plan, 2021, superseded in December 2025

> “Once data is analyzed this would, depending on results, be used by Mandos to submit an NDA to FDA by December 2023 and then publish data while working with FDA on the response, such that publication would be expected in the second quarter of 2024.”
> “In this study, we will use information from the YODA NPC registry to add to the pool of control patients that can be used for case-control and natural history comparator studies to show a long-term effect of adrabetadex that will, if a sufficiently strong result, contribute to a registration application by Mandos for accelerated approval at FDA.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-2.1.1-30"></a>

### Pivotal results timing, April 2017, superseded in November 2018

> “Results from the pivotal trial are expected in mid-2018.”

Source: [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)

<a id="topic-2.1.1-31"></a>

### Launch timing, April 2017, superseded in November 2018

> “Product is expected to be launched and accretive to earnings beginning in 2019”

Source: [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
